{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:48:19Z","timestamp":1792172899185,"version":"4.4.0"},"reference-count":48,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T00:00:00Z","timestamp":1229990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Objectives.\u2002<\/jats:bold> To study the evidence on the efficacy and safety of ezetimibe monotherapy for the treatment of primary (heterozygous familial and non\u2010familial) hypercholesterolaemia.<\/jats:p><jats:p><jats:bold>Design.\u2002<\/jats:bold> Systematic review and meta\u2010analysis of randomized controlled trials (RCTs).<\/jats:p><jats:p><jats:bold>Methods.\u2002<\/jats:bold> Eleven electronic bibliographic databases covering the biomedical, scientific and grey literature were searched from inception and supplemented by contact with experts in the field. Two reviewers independently determined the eligibility of RCTs, with a minimum treatment duration of 12\u2003weeks, which compared ezetimibe monotherapy (10\u2003mg per day) with placebo.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> In the absence of data from clinical outcome trials, surrogate endpoints such as changes in lipid concentrations were used as indicators of clinical outcomes. A meta\u2010analysis of eight randomized, double\u2010blind, placebo\u2010controlled trials (all 12\u2003weeks) showed that ezetimibe monotherapy was associated with a statistically significant mean reduction in LDL cholesterol (from baseline to endpoint) of \u221218.58%, (95% CI: \u221219.67 to \u221217.48, <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.00001) compared with placebo. Significant (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.00001) changes were also found in total cholesterol (\u221213.46%, 95% CI: \u221214.22 to \u221212.70), HDL cholesterol (3.00%, 95% CI: 2.06\u20133.94) and triglyceride levels (\u22128.06%, 95% CI: \u221210.92 to \u22125.20). Ezetimibe monotherapy appeared to be well tolerated with a safety profile similar to placebo.<\/jats:p><jats:p><jats:bold>Conclusions.\u2002<\/jats:bold> In a meta\u2010analysis restricted to short\u2010term trials in hypercholesterolaemia, significant potentially favourable changes in lipid and lipoprotein levels relative to baseline occurred with ezetimibe monotherapy. Further long\u2010term studies with cardiovascular and other clinical outcome data are needed to assess the efficacy and safety of ezetimibe more fully.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2008.02062.x","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T12:45:16Z","timestamp":1230036316000},"page":"568-580","source":"Crossref","is-referenced-by-count":211,"title":["Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"265","author":[{"given":"A.","family":"Pandor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tumur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paisley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Duenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chilcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,6]]},"reference":[{"key":"e_1_2_9_2_2","volume-title":"Coronary Heart Disease Statistics 2007 Edition","author":"Allender S","year":"2007"},{"key":"e_1_2_9_3_2","volume-title":"European Cardiovascular Disease Statistics 2005 Edition","author":"Peterson S","year":"2005"},{"issue":"5","key":"e_1_2_9_4_2","first-page":"v1","article-title":"JBS 2: Joint British Societies\u2019 guidelines on prevention of cardiovascular disease in clinical practice","volume":"91","author":"British Cardiac Society","year":"2005","journal-title":"Heart"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.9.567"},{"key":"e_1_2_9_6_2","first-page":"1","article-title":"Cholesterol and coronary heart disease: screening and treatment","volume":"4","author":"NHS Centre for Reviews and Dissemination","year":"1998","journal-title":"Eff Health Care Bull"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.08.024"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000133317.49796.0E"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta12210"},{"key":"e_1_2_9_11_2","unstructured":"NHS.Prescription cost analysis England 2005. London:NHS Health and Social Care Information Centre Health Care Statistics.2006. Available from:http:\/\/www.ic.nhs.uk\/pubs\/prescostanalysis2005(9 October 2006)."},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340270029025"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.09.013"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"e_1_2_9_15_2","unstructured":"National Institute for Health and Clinical Excellence (NICE).NICE technology appraisal guidance 132 \u2013 Ezetimibe for the treatment of primary (heterozygous\u2010familial and non\u2010familial) hypercholesterolaemia. London:NICE 2007. Available from:http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA132guidance.pdf(30th November 2007)."},{"key":"e_1_2_9_16_2","unstructured":"European Medicines Agency (EMEA).Committee for Medical Products for Human Use (CHMP) \u2013 note for guidance on clinical investigation of medical products in the treatment of lipid disorders. London:EMEA2004. Available from:http:\/\/emea.europa.eu\/pdfs\/human\/ewp\/302003en.pdf(14th November 2006)."},{"key":"e_1_2_9_17_2","unstructured":"NHS Centre for reviews and Dissemination.Undertaking systematic reviews of research on effectiveness \u2013 CRD\u2019s guidance for those carrying out or commissioning reviews (Report 4). York:University of York 2001."},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)62352-5"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(99)00026-4"},{"key":"e_1_2_9_20_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]","author":"Higgins JPT","year":"2006"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068312.21969.C8"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.016"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02610-4"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02798-4"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.5.620"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)03236-8"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00807-2"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00803-5"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.1.356"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400190110021"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1423"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.10.946"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.085"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.10.031"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.07.011"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800742"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804602"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0806603"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01068.x"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0807372"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-4-18"},{"key":"e_1_2_9_43_2","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2006"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60716-8"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.725"},{"key":"e_1_2_9_46_2","article-title":"Cost\u2010effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contra\u2010indications \u2010 A markov model","author":"Ara R","journal-title":"Am J Cardiovasc Drugs"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312013092204"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01085-X"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2008.02062.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2008.02062.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:12:16Z","timestamp":1697087536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2008.02062.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,6]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1365-2796.2008.02062.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2008.02062.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,6]]}}}